May. 18 at 2:56 PM
$CUE - IMMUNE MODULATION + BIOPHARMA PIPELINE 👇
Cue Biopharma is quietly building a precision immunology platform that targets disease-specific T cells — without the systemic toxicity of broad immune activators. Real science, real partnerships.
What's standing out:
🔹 Boehringer Ingelheim deal worth up to
$345M in milestones —
$7.5M earned in April 2026
🔹 New CEO Shao-Lee Lin, M.D., Ph.D. — founder of ACELYRIN, IPO'd at
$2B+ valuation
🔹
$27.6M private placement closed May 4 — runway to advance the pipeline
🔹 Q1 2026 collaboration revenue hit
$5.7M vs
$0.4M a year ago — net loss narrowing fast
Watch for:
The phase 2 data from the Ascendant-221 China CSU study is expected in 2H 2026, and CUE expects to file an IND amendment with the FDA to expand into food allergy — also in 2H 2026. Multiple binary readouts stacking up in the back half of the year. If any of these land, this story moves fast.
Communicated Disclaimer - https://stockresearchtoday.com/cue/
$AIM $HCAI $CREG
